Key result
Intravenously administered edrophonium chloride abruptly terminated supraventricular tachycardia in 75% (12 of 16) of cases, with transient side effects occurring in 31.3% of patients.
Why the study?
Does intravenous edrophonium chloride terminate supraventricular tachycardias in affected patients?
Observational (n=16)
Does intravenous edrophonium chloride terminate supraventricular tachycardias in affected patients?
Intravenous edrophonium chloride effectively and abruptly terminated supraventricular tachycardia in 75% of cases with only transient, self-resolving side effects.
Answers are grounded in this paper and cite their sources.
May support edrophonium for acute SVT termination; leaves open efficacy and safety pending controlled trials.
Twelve of 16 (75%) supraventricular tachycardias were abruptly terminated by intravenously administered edrophonium chloride (Tensilon) in doses ranging from 5 to 20 mg. Transient side effects of the drug were seen in five patients (31.3%) and subsided spontaneously as the drug effect was rapidly dissipated. The experience of other investigators is reviewed and the mechanism of drug action is discussed. Despite little recognition to date as an antiarrhythmic agent, edrophonium may prove to be the initial drug treatment of choice in managing a variety of supraventricular tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
John D. Cantwell (1972) conducted an observational in Supraventricular tachyarrhythmias (n=16). Intravenous edrophonium chloride (Tensilon) was evaluated on Abrupt termination of supraventricular tachycardia. Intravenously administered edrophonium chloride abruptly terminated supraventricular tachycardia in 75% (12 of 16) of cases, with transient side effects occurring in 31.3% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: